Clinical trial for the evaluation of the efficacy and safety of HP-01 on blood flow improvement
- Conditions
- Endocrine, nutritional and metabolic disease
- Registration Number
- KCT0004455
- Lead Sponsor
- Hanpoong Pharm & Foods
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
1) The subjects who agrees to participate in this study before the start of the study and who has signed the informed consent form
2) The subjects whose age over 25 and over, 70 and less
3) The subjects who satisfy three or more items under the following conditions:
A. The subjects with a fasting total cholesterol of 200 to 239mg/dl
B. The subjects with a fasting LDL-cholesterol of 130 to 159mg/dl
C. The subjects with a fasting blood sugar of 100 to 125mg/dl
D. The subjects with a systolic blood pressure of 120 to 139mmHg
E. The subjects with a BMI(Body mass index) of over 25 kg/? and less than 30 kg/?
F. The subjects with a Waist to hip ratio of over than 0.9 male and 0.85 female
1) The patients with uncontrolled hypertension(systolic blood pressure over 160mmHg or diastolic blood pressure over than 100mmHg, after 10 minutes of stabilization)
2) The patients with uncontrolled diabetes mellitus(fasting blood sugar over than 180mg/dl)
3) The subjects, who is deemed unfit for this human an application test by the investigator
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Platelet aggregability;Treatment emergent adverse events
- Secondary Outcome Measures
Name Time Method